Pharmacological treatment is estimated to represent 52.0% of treatment modality in 2026; anti-VEGF therapies account for 47.0% of product; hospital pharmacies hold 46.0% of distribution channel. Demand follows confirmed retinal disease and specialist treatment capacity, but repeated visits and missed follow-up restrict treatment persistence.
Diabetes Associated Ophthalmic Treatment Market Analysis By ApplicationDiabetes Associated Ophthalmic Treatment Market Analysis By Distribution ChannelDiabetes Associated Ophthalmic Treatment Market Analysis By End UserDiabetes Associated Ophthalmic Treatment Market Analysis By Treatment ModalityDiabetes Associated Ophthalmic Treatment Market Breakdown By Product, Application, And Region